Conduit Pharmaceuticals (FRA:ZK70) Debt-to-EBITDA : -2.17 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Conduit Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €7.02 Mil. Conduit Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.10 Mil. Conduit Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2024 was €-3.29 Mil. Conduit Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -2.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Conduit Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

FRA:ZK70' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.47 Med: -0.32 Max: 0.32
Current: -0.47

During the past 4 years, the highest Debt-to-EBITDA Ratio of Conduit Pharmaceuticals was 0.32. The lowest was -0.47. And the median was -0.32.

FRA:ZK70's Debt-to-EBITDA is ranked worse than
100% of 281 companies
in the Biotechnology industry
Industry Median: 1.54 vs FRA:ZK70: -0.47

Conduit Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Conduit Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Debt-to-EBITDA Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-EBITDA

-0.24

-0.41

0.32

-0.47

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial							0.07	-0.09	-0.06	-0.11	-2.17

Competitive Comparison of Conduit Pharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, Conduit Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conduit Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Conduit Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Conduit Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(7.019	+	0.102)	/	-15.136
	=	-0.47

Conduit Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(7.019	+	0.102)	/	-3.288
	=	-2.17

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.

Conduit Pharmaceuticals (FRA:ZK70) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Conduit Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CDT:USA

Address

4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines